The role of cytokines in hepatocellular carcinoma

Journal of Leukocyte Biology

Volumn 80, Issue 6, 2006, Pages 1197-1213

  Budhu, Anuradha ^a   Xin, Wei Wang ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Hepatitis; Immune; Inflammation; Liver; Metastasis

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; PEGINTERFERON; RIBAVIRIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ACUTE HEPATITIS; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CARCINOGENESIS; CHRONIC INFLAMMATION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METASTASIS; MICROENVIRONMENT; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL; TH2 CELL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; HEPATITIS B; HEPATITIS C; HUMANS; INFLAMMATION; LIVER NEOPLASMS; NEOPLASM METASTASIS; TH1 CELLS; TH2 CELLS;

EID: 33845420396     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0506297     Document Type: Review

References (174)

1. Balkwill, F., Mantovani, A. (2001) Inflammation and cancer: back to Virchow? Lancet 357, 539-545.
2. Ohno, S., Inagawa, H., Dhar, D. K., Fujii, T., Ueda, S., Tachibana, M., Suzuki, N., Inoue, M., Soma, G., Nagasue, N. (2003) The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res. 23, 5015-5022.
3. Coca, S., Perez-Piqueras, J., Martinez, D., Colmenarejo, A., Saez, M. A., Vallejo, C., Martos, J. A., Moreno, M. (1997) The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79, 2320-2328.
4. Ribatti, D., Ennas, M. G., Vacca, A., Ferreli, F., Nico, B., Orru, S., Sirigu, P. (2003) Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur. J. Clin. Invest. 33, 420-425.
5. Leek, R. D., Landers, R. J., Harris, A. L., Lewis, C. E. (1999) Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 79, 991-995.
6. Imada, A., Shijubo, N., Kojima, H., Abe, S. (2000) Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur. Respir. J. 15, 1087-1093.
7. Lewis, C. E., Pollard, J. W. (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66, 605-612.
8. Coussens, L. M., Werb, Z. (2002) Inflammation and cancer. Nature 420, 860-867.
9. Balkwill, F., Charles, K. A., Mantovani, A. (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217.
10. Finch, C. E., Crimmins, E. M. (2004) Inflammatory exposure and historical changes in human life-spans. Science 305, 1736-1739.
11. Enzler, T., Gillessen, S., Manis, J. P., Ferguson, D., Fleming, J., Alt, F. W., Mihm, M., Dranoff, G. (2003) Deficiencies of GM-CSF and interferon γ link inflammation and cancer. J. Exp. Med. 197, 1213-1219.
12. Dannenberg, A. J., Subbaramaiah, K. (2003) Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4, 431-436.
13. Hussain, S. P., Hofseth, L. J., Harris, C. C. (2003) Radical causes of cancer. Nat. Rev. Cancer 3, 276-285.
14. Wiltrout, R. H. (2000) Regulation and antimetastatic functions of liver-associated natural killer cells. Immunol. Rev. 174, 63-76.
15. De Lalla, C., Galli, G., Aldrighetti, L., Romeo, R., Mariani, M., Monno, A., Nuti, S., Colombo, M., Callea, F., Porcelli, S. A., Panina-Bordignon, P., Abrignani, S., Casorati, G., Dellabona, P. (2004) Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J. Immunol. 173, 1417-1425.
16. De Visser, K. E., Coussens, L. M. (2005) The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol. Immunother. 54, 1143-1152.
17. Mann, J. R., Backlund, M. G., DuBois, R. N. (2005) Mechanisms of disease: inflammatory mediators and cancer prevention. Nat. Clin. Pract. Oncol. 2, 202-210.
18. Pisani, P., Parkin, D. M., Bray, F., Ferlay, J. (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer 83, 18-29.
19. Tang, Z. Y. (2001) Hepatocellular carcinoma - cause, treatment and metastasis. World J. Gastroenterol. 7, 445-454.
20. Yuki, K., Hirohashi, S., Sakamoto, M., Kanai, T., Shimosato, Y. (1990) Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 66, 2174-2179.
21. Nakakura, E. K., Choti, M. A. (2000) Management of hepatocellular carcinoma. Oncology (Williston Park) 14, 1085-1098.
22. Anzola, M. (2004) Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J. Viral Hepat. 11, 383-393.
23. Tsai, J. F., Jeng, J. E., Ho, M. S., Chang, W. Y., Hsieh, M. Y., Lin, Z. Y., Tsai, J. H. (1997) Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br. J. Cancer 76, 968-974.
24. Donato, F., Boffetta, P., Puoti, M. (1998) A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer 75, 347-354.
25. Brechot, C., Jaffredo, F., Lagorce, D., Gerken, G., Meyer zum Buschenfelde, K., Papakonstontinou, A., Hadziyannis, S., Romeo, R., Colombo, M., Rodes, J., Bruix, J., Williams, R., Naoumov, N. (1998) Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J. Hepatol. 29, 173-183.
26. Major, M. E., Feinstone, S. M. (1997) The molecular virology of hepatitis C. Hepatology 25, 1527-1538.
27. Di Bisceglie, A. M. (1998) Hepatitis C. Lancet 351, 351-355.
28. Stroffolini, T., Andreone, P., Andriulli, A., Ascione, A., Craxi, A., Chiaramonte, M., Galante, D., Manghisi, O. G., Mazzanti, R., Medaglia, C., Pilleri, G., Rapaccini, G. L., Simonetti, R. G., Taliani, G., Tosti, M. E., Villa, E., Gasbarrini, G. (1998) Characteristics of hepatocellular carcinoma in Italy. J. Hepatol. 29, 944-952.
29. Urashima, T., Saigo, K., Kobayashi, S., Imaseki, H., Matsubara, H., Koide, Y., Asano, T., Kondo, Y., Koike, K., Isono, K. (1997) Identification of hepatitis B virus integration in hepatitis C virus- infected hepatocellular carcinoma tissues. J. Hepatol. 26, 771-778.
30. Zhang, J. Y., Dai, M., Wang, X., Lu, W. Q., Li, D. S., Zhang, M. X., Wang, K. J., Dai, L. P., Han, S. G., Zhou, Y. F., Zhuang, H. (1998) A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China. Int. J. Epidemiol. 27, 574-578.
31. Sun, C. A., Farzadegan, H., You, S. L., Lu, S. N., Wu, M. H., Wolfe, L., Hardy, W., Huang, G. T., Yang, P. M., Lee, H., Chen, C. J. (1996) Mutual confounding and interactive effects between hepatitis C and hepatitis B viral infections in hepatocellular carcinogenesis: a population-based case-control study in Taiwan. Cancer Epidemiol. Biomarkers Prev. 5, 173-178.
32. Tsai, J. F., Jeng, J. E., Ho, M. S., Chang, W. Y., Lin, Z. Y., Tsai, J. H. (1994) Hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Chinese: a case-control study. Int. J. Cancer 56, 619-621.
33. Donato, F., Tagger, A., Chiesa, R., Ribero, M. L., Tomasoni, V., Fasola, M., Gelatti, U., Portera, G., Boffetta, P., Nardi, G. (1997) Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. Hepatology 26, 579-584.
34. Brechot, C., Gozuacik, D., Murakami, Y., Paterlini-Brechot, P. (2000) Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin. Cancer Biol. 10, 211-231.
35. Seeger, C., Mason, W. S. (2000) Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64, 51-68.
36. Butel, J. S. (2000) Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 21, 405-426.
37. Andrisani, O. M., Barnabas, S. (1999) The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis (Review). Int. J. Oncol. 15, 373-379.
38. Feitelson, M. A. (1999) Hepatitis B virus in hepatocarcinogenesis. J. Cell. Physiol. 181, 188-202.
39. Giannini, C., Brechot, C. (2003) Hepatitis C virus biology. Cell Death Differ. 10, Suppl 1, S27-S38.
40. Suzuki, R., Suzuki, T., Ishii, K., Matsuura, Y., Miyamura, T. (1999) Processing and functions of Hepatitis C virus proteins. Intervirology 42, 145-152.
41. Tanaka, S., Wands, J. R. (1996) Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor β 1-induced apoptosis. Cancer Res. 56, 3391-3394.
42. Stroffolini, T., Chiaramonte, M., Tiribelli, C., Villa, E., Simonetti, R. G., Rapicetta, M., Stazi, M. A., Bertin, T., Croce, S. L., Trande, P. (1992) Hepatitis C virus infection, HBsAg carrier state and hepatocellular carcinoma: relative risk and population attributable risk from a case-control study in Italy. J. Hepatol. 16, 360-363.
43. Cordier, S., Le, T. B., Verger, P., Bard, D., Le, C. D., Larouze, B., Dazza, M. C., Hoang, T. Q., Abenhaim, L. (1993) Viral infections and chemical exposures as risk factors for hepatocellular carcinoma in Vietnam. Int. J. Cancer 55, 196-201.
44. Kaklamani, E., Trichopoulos, D., Tzonou, A., Zavitsanos, X., Koumantaki, Y., Hatzakis, A., Hsieh, C. C., Hatziyannis, S. (1991) Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 265, 1974-1976.
45. Nakamoto, Y., Guidotti, L. G., Kuhlen, C. V., Fowler, P., Chisari, F. V. (1998) Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 188, 341-350.
46. Nakamura, I., Imawari, M. (2000) Cellular immune response in HCV infection. J. Gastroenterol. 35, 881-889.
47. Rehermann, B. (2003) Immune responses in hepatitis B virus infection. Semin. Liver Dis. 23, 21-38.
48. Rehermann, B. (2000) Intrahepatic T cells in hepatitis B: viral control versus liver cell injury. J. Exp. Med. 191, 1263-1268.
49. Freeman, A. J., Marinos, G., Ffrench, R. A., Lloyd, A. R. (2001) Immunopathogenesis of hepatitis C virus infection. Immunol. Cell Biol. 79, 515-536.
50. Rapicetta, M., Ferrari, C., Levrero, M. (2002) Viral determinants and host immune responses in the pathogenesis of HBV infection. J. Med. Virol. 67, 454-457.
51. Guidotti, L. G., Rochford, R., Chung, J., Shapiro, M., Purcell, R., Chisari, F. V. (1999) Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 825-829.
52. Kakimi, K., Lane, T. E., Wieland, S., Asensio, V. C., Campbell, I. L., Chisari, F. V., Guidotti, L. G. (2001) Blocking chemokine responsive to γ-2/interferon (IFN)-γ inducible protein and monokine induced by IFN-γ activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J. Exp. Med. 194, 1755-1766.
53. Toyonaga, T., Hino, O., Sugai, S., Wakasugi, S., Abe, K., Shichiri, M., Yamamura, K. (1994) Chronic active hepatitis in transgenic mice expressing interferon-γ in the liver. Proc. Natl. Acad. Sci. USA 91, 614-618.
54. Ando, K., Moriyama, T., Guidotti, L. G., Wirth, S., Schreiber, R. D., Schlicht, H. J., Huang, S. N., Chisari, F. V. (1993) Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J. Exp. Med. 178, 1541-1554.
55. Koike, K. (2002) Hepatocarcinogenesis in hepatitis viral infection: lessons from transgenic mouse studies. J. Gastroenterol. 37 (Suppl. 13), 55-64.
56. Krawczynski, K., Alter, M. J., Tankersley, D. L., Beach, M., Robertson, B. H., Lambert, S., Kuo, G., Spelbring, J. E., Meeks, E., Sinha, S., Carson, D. A. (1996) Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J. Infect. Dis. 173, 822-828.
57. Wakita, T., Katsume, A., Kato, J., Taya, C., Yonekawa, H., Kanegae, Y., Saito, I., Hayashi, Y., Koike, M., Miyamoto, M., Hiasa, Y., Kohara, M. (2000) Possible role of cytotoxic T cells in acute liver injury in hepatitis C virus cDNA transgenic mice mediated by Cre/loxP system. J. Med. Virol. 62, 308-317.
58. Ngui, S. L., Hallet, R., Teo, C. G. (1999) Natural and iatrogenic variation in hepatitis B virus. Rev. Med. Virol. 9, 183-209.
59. Gomez, J., Martell, M., Quer, J., Cabot, B., Esteban, J. I. (1999) Hepatitis C viral quasispecies. J. Viral Hepat. 6, 3-16.
60. Martell, M., Esteban, J. I., Quer, J., Genesca, J., Weiner, A., Esteban, R., Guardia, J., Gomez, J. (1992) Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66, 3225-3229.
61. Horie, C., Iwahana, H., Horie, T., Shimizu, I., Yoshimoto, K., Yogita, S., Tashiro, S., Ito, S., Itakura, M. (1996) Detection of different quasispecies of hepatitis C virus core region in cancerous and noncancerous lesions. Biochem. Biophys. Res. Commun. 218, 674-681.
62. Bertoletti, A., Costanzo, A., Chisari, F. V., Levrero, M., Artini, M., Sette, A., Penna, A., Giuberti, T., Fiaccadori, F., Ferrari, C. (1994) Cytotoxic T lymphocyte response to a wild-type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J. Exp. Med. 180, 933-943.
63. Bertoletti, A., Sette, A., Chisari, F. V., Penna, A., Levrero, M., De Carli, M., Fiaccadori, F., Ferrari, C. (1994) Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369, 407-410.
64. Lanzavecchia, A. (1997) Understanding the mechanisms of sustained signaling and T cell activation. J. Exp. Med. 185, 1717-1719.
65. Evavold, B. D., Allen, P. M. (1991) Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 252, 1308-1310.
66. Sloan-Lancaster, J., Evavold, B. D., Allen, P. M. (1993) Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363, 156-159.
67. Kim, Y. C., Song, K. S., Yoon, G., Nam, M. J., Ryu, W. S. (2001) Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis. Oncogene 20, 16-23.
68. Forgues, M., Difilippantonio, M. J., Linke, S. P., Ried, T., Nagashima, K., Feden, J., Valerie, K., Fukasawa, K., Wang, X. W. (2003) Involvement of Crm1 in HBx-induced aberrant centriole replication and abnormal mitotic spindles. Mol. Cell. Biol., In press.
69. Wang, W., Budhu, A., Forgues, M., Wang, X. W. (2005) Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat. Cell Biol. 7, 823-830.
70. Large, M. K., Kittlesen, D. J., Hahn, Y. S. (1999) Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J. Immunol. 162, 931-938.
71. You, L. R., Chen, C. M., Lee, Y. H. W. (1999) Hepatitis C virus core protein enhances NF-κB signal pathway triggering by lymphotoxin-β receptor ligand and tumor necrosis factor α. J. Virol. 73, 1672-1681.
72. Lee, C. H., Choi, Y. H., Yang, S. H., Lee, C. W., Ha, S. J., Sung, Y. C. (2001) Hepatitis C virus core protein inhibits interleukin 12 and nitric oxide production from activated macrophages. Virology 279, 271-279.
73. Soguero, C., Joo, M., Chianese-Bullock, K. A., Nguyen, D. T., Tung, K., Hahn, Y. S. (2002) Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J. Virol. 76, 9345-9354.
74. Wu, C. G., Budhu, A., Chen, S., Zhou, X., Popescu, N. C., Valerie, K., Wang, X. W. (2006) Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocyte. Mol. Med., In press.
75. Chan-Fook, C., Jiang, W. R., Clarke, B. E., Zitzmann, N., Maidens, C., McKeating, J. A., Jones, I. M. (2000) Hepatitis C virus glycoprotein E2 binding to CD81: the role of E1E2 cleavage and protein glycosylation in bioactivity. Virology 273, 60-66.
76. Reyes, G. R. (2002) The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J. Biomed. Sci. 9, 187-197.
77. Carretero, M., Gomez-Gonzalo, M., Lara-Pezzi, E., Benedicto, I., Aramburu, J., Martinez-Martinez, S., Redondo, J., Lopez-Cabrera, M. (2002) The hepatitis B virus X protein binds to and activates the NH(2)-terminal trans-activation domain of nuclear factor of activated T cells-1. Virology 299, 288-300.
78. Hofseth, L. J., Saito, S., Hussain, S. P., Espey, M. G., Miranda, K. M., Araki, Y., Jhappan, C., Higashimoto, Y., He, P., Linke, S. P., Quezado, M. M., Zurer, I., Rotter, V., Wink, D. A., Appella, E., Harris, C. C. (2003) Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc. Natl. Acad. Sci. USA 100, 143-148.
79. Hussain, S. P., Raja, K., Amstad, P. A., Sawyer, M., Trudel, L. J., Wogan, G. N., Hofseth, L. J., Shields, P. G., Billiar, T. R., Trautwein, C., Hohler, T., Galle, P. R., Phillips, D. H., Markin, R., Marrogi, A. J., Harris, C. C. (2000) Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: oxyradical overload diseases. Proc. Natl. Acad. Sci. USA 97, 12770-12775.
80. Hagen, T. M., Huang, S., Curnutte, J., Fowler, P., Martinez, V., Wehr, C. M., Ames, B. N., Chisari, F. V. (1994) Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 91, 12808-12812.
81. Kitaoka, S., Shiota, G., Kawasaki, H. (2003) Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C. Hepatogastroenterology 50, 1569-1574.
82. Huang, Y. S., Hwang, S. J., Chan, C. Y., Wu, J. C., Chao, Y., Chang, F. Y., Lee, S. D. (1999) Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua Yi Xue Za Zhi (Taipei) 62, 327-333.
83. Bortolami, M., Venturi, C., Giacomelli, L., Scalerta, R., Bacchetti, S., Marino, F., Floreani, A., Lise, M., Naccarato, R., Farinati, F. (2002) Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer. Dig. Liver Dis. 34, 794-801.
84. Nakazaki, H. (1992) Preoperative and postoperative cytokines in patients with cancer. Cancer 70, 709-713.
85. Song, l. H., Binh, V. Q., Duy, D. N., Kun, J. F., Bock, T. C., Kremsner, P. G., Luty, A. J. (2003) Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus. J. Clin. Virol. 28, 93-103.
86. Sato, T., Asanuma, Y., Masaki, Y., Sato, Y., Hatakeyama, Y., Kusano, T., Koyama, K. (1996) Changes in tumor necrosis factor-a and interleukin-1 β production following liver surgery on cirrhotic patients. Hepatogastroenterology 43, 1148-1153.
87. Wang, Y., Kato, N., Hoshida, Y., Yoshida, H., Taniguchi, H., Goto, T., Moriyama, M., Otsuka, M., Shiina, S., Shiratori, Y., Ito, Y., Omata, M. (2003) Interleukin-1β gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 37, 65-71.
88. Tanaka, Y., Furuta, T., Suzuki, S., Orito, E., Yeo, A. E., Hirashima, N., Sugauchi, F., Ueda, R., Mizokami, M. (2003) Impact of interleukin-1β genetic polymorphisms on the development of hepatitis C virus-related hepatocellular carcinoma in Japan. J. Infect. Dis. 187, 1822-1825.
89. Hirankarn, N., Kimkong, I., Kummee, P., Tangkijvanich, P., Poovorawan, Y. (2006) Interleukin-1β gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection. World J. Gastroenterol. 12, 776-779.
90. Ikeguchi, M., Hirooka, Y. (2005) Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas. Onkologie 28, 255-259.
91. Morshed, S. A., Fukuma, H., Kimura, Y., Watanabe, S., Nishioka, M. (1993) Interferon-γ, interleukin (IL)-2 and IL-2 receptor expressions in hepatitis C virus-infected liver. Gastroenterol. Jpn. 28, Suppl 5, 59-66.
92. Cao, Z. X., Chen, X. P., Wu, Z. D. (2003) Effects of splenectomy in patients with cirrhosis undergoing hepatic resection for hepatocellular carcinoma. World J. Gastroenterol. 9, 2460-2463.
93. Chia, C. S., Ban, K., Ithnin, H., Singh, H., Krishnan, R., Mokhtar, S., Malihan, N., Seow, H. F. (2002) Expression of interleukin-18, interferon-γ and interleukin-10 in hepatocellular carcinoma. Immunol. Lett. 84, 163-172.
94. d'Arville, C. N., Nouri-Aria, K. T., Johnson, P., Williams, R. (1993) Gene expression regulation for interferon-α in hepatocellular carcinoma. J. Hepatol. 17, 339-346.
95. Tangkijvanich, P., Vimolket, T., Theamboonlers, A., Kullavanijaya, P., Suwangool, P., Poovorawan, Y. (2000) Serum interleukin-6 and interferon-γ levels in patients with hepatitis B-associated chronic liver disease. Asian Pac. J. Allergy Immunol. 18, 109-114.
96. Migita, K., Miyazoe, S., Maeda, Y., Daikoku, M., Abiru, S., Ueki, T., Yano, K., Nagaoka, S., Matsumoto, T., Nakao, K., Hamasaki, K., Yatsuhashi, h., Ishibashi, H., Eguchi, K. (2005) Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection-association between TGF-β1 polymorphisms and hepatocellular carcinoma. J. Hepatol. 42, 505-510.
97. Ben Ari, Z., Mor, E., Papo, O., Kfir, B., Sulkes, J., Tambur, A. R., Tur-Kaspa, R., Klein, T. (2003) Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am. J. Gastroenterol. 98, 144-150.
98. Nieters, A., Yuan, J. M., Sun, C. L., Zhang, Z. Q., Stoehlmacher, J., Govindarajan, S., Yu, M. C. (2005) Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer 103, 740-748.
99. Kakumu, S., Okumura, A., Ishikawa, T., Yano, M., Enomoto, A., Nishimura, H., Yoshioka, K., Yoshika, Y. (1997) Serum levels of IL-10, IL-15 and soluble tumor necrosis factor-α (TNF-α) receptors in type C chronic liver disease. Clin. Exp. Immunol. 109, 458-463.
100. Zekri, A. R., Ashour, M. S., Hassan, A., Alam El-Din, H. M., El Shehaby, A. M., Abu-Shady, M. A. (2005) Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World J. Gastroenterol. 11, 6624-6630.
101. Itoh, Y., Okanoue, T., Ohnishi, N., Nishioji, K., Sakamoto, S., Nagao, Y., Nakamura, H., Kirishima, T., Kashima, K. (1999) Hepatic damage induced by transcatheter arterial chemoembolization elevates serum concentrations of macrophage-colony stimulating factor. Liver 19, 97-103.
102. McGuinness, P. H., Painter, D., Davies, S., McCaughan, G. W. (2000) Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 46, 260-269.
103. Ho, S. Y., Wang, Y. J., Chen, H. L., Chen, C. H., Chang, C. J., Wang, P. J., Chen, H. H., Guo, H. R. (2004) Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-α promoter gene. Cancer Causes Control 15, 657-663.
104. Heneghan, M. A., Johnson, P. J., Clare, M., Ho, S., Harrison, P. M., Donaldson, P. T. (2003) Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int. J. Gastrointest. Cancer 34, 19-26.
105. Kroeger, K. M., Carville, K. S., Abraham, L. J. (1997) The -308 tumor necrosis factor-α promoter polymorphism effects transcription. Mol. Immunol. 34, 391-399.
106. Niro, G. A., Fontana, R., Gioffreda, D., Valvano, M. R., Lacobellis, A., Facciorusso, D., Andriulli, A. (2005) Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int. 25, 1175-1181.
107. Beckebaum, S., Zhang, X., Chen, X., Yu, Z., Frilling, A., Dworacki, G., Grosse-Wilde, H., Broelsch, C. E., Gerken, G., Cicinnati, V. R. (2004) Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin. Cancer Res. 10, 7260-7269.
108. Chau, G. Y., Wu, C. W., Lui, W. Y., Chang, T. J., Kao, H. L., Wu, L. H., King, K. L., Loong, C. C., Hsia, C. Y., Chi, C. W. (2000) Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann. Surg. 231, 552-558.
109. Shin, H. D., Park, B. L., Kim, L. H., Jung, J. H., Kim, J. Y., Yoon, J. H., Kim, Y. J., Lee, H. S. (2003) Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum. Mol. Genet. 12, 901-906.
110. Hu, R. H., Lee, P. H., Yu, S. C. (1999) Secretion of acute-phase proteins before and after hepatocellular carcinoma resection. J. Formos. Med. Assoc. 98, 85-91.
111. Lee, Y., Park, U. S., Choi, I., Yoon, S. K., Park, Y. M., Lee, Y. I. (1998) Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells. Clin. Cancer Res. 4, 1711-1717.
112. Kanaoka, Y., Yagi, T., Sadamori, H., Matsukawa, H., Matsuda, H., Inagaki, M., Ishikawa, T., Saito, S., Iwagaki, H., Tanaka, N. (2002) Analysis of host response to hepatectomy by simultaneous measurement of cytokines in the portal vein, caval vein and radial artery. J. Int. Med. Res. 30, 496-505.
113. Ishikawa, M., Miyauchi, T., Yagi, K., Chikaishi, H., Fukuta, Y., Miyake, H., Harada, M., Yogita, S., Tashiro, S. (1999) Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J. Surg. 23, 75-79.
114. Reichner, J. S., Mulligan, J. A., Spisni, R., Sotomayor, E. A., Albina, J. E., Bland, K. I. (1998) Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells. Ann. Surg. Oncol. 5, 279-286.
115. Coskun, U., Bukan, N., Sancak, B., Gunel, N., Ozenirler, S., Unal, A., Yucel, A. (2004) Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions. Neoplasma 51, 209-213.
116. Park, B. L., Lee, H. S., Kim, Y. J., Kim, J. Y., Jung, J. H., Kim, L. H., Shin, H. D. (2003) Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp. Mol. Med. 35, 76-82.
117. Grasl-Kraupp, B., Rossmanith, W., Ruttkay-Nedecky, B., Mullauer, L., Kammerer, B., Bursch, W., Schulte-Hermann, R. (1998) Levels of transforming growth factor β and transforming growth factor β receptors in rat liver during growth, regression by apoptosis and neoplasia. Hepatology 28, 717-726.
118. Jaskiewicz, K., Chasen, M. R. (1995) Differential expression of transforming growth factor α, adhesions molecules and integrins in primary, metastatic liver tumors and in liver cirrhosis. Anticancer Res. 15, 559-562.
119. Yuen, M. F., Norris, S., Evans, L. W., Langley, P. G., Hughes, R. D. (2002) Transforming growth factor-β 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis. Scand. J. Gastroenterol. 37, 233-238.
120. Kim, Y. J., Lee, H. S., Im, J. P., Min, B. H., Kim, H. D., Jeong, J. B., Yoon, J. H., Kim, C. Y., Kim, M. S., Kim, J. Y., Jung, J. H., Kim, L. H., Park, B. L., Shin, H. D. (2003) Association of transforming growth factor-β1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp. Mol. Med. 35, 196-202.
121. Okumoto, K., Hattori, E., Tamura, K., Kiso, S., Watanabe, H., Saito, K., Saito, T., Togashi, H., Kawata, S. (2004) Possible contribution of circulating transforming growth factor-β1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int. 24, 21-28.
122. Sasaki, Y., Tsujiuchi, T., Murata, N., Tsutsumi, M., Konishi, Y. (2001) Alterations of the transforming growth factor-β signaling pathway in hepatocellular carcinomas induced endogenously and exogenously in rats. Jpn. J. Cancer Res. 92, 16-22.
123. Akbar, S. M., Abe, M., Murakami, H., Tanimoto, K., Kumagi, T., Yamashita, Y., Michitaka, K., Horiike, N., Onji, M. (2001) Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett. 171, 125-132.
124. Simonetti, R. G., Liberati, A., Angiolini, C., Pagliaro, L. (1997) Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann. Oncol. 8, 117-136.
125. Camma, C., Di Bona, D., Craxi, A. (2004) The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr. Pharm. Des. 10, 2123-2130.
126. Akiba, J., Yano, H., Ogasawara, S., Higaki, K., Kojiro, M. (2001) Expression and function of interleukin-8 in human hepatocellular carcinoma. Int. J. Oncol. 18, 257-264.
127. Hira, E., Ono, T., Dhar, D. K., El Assal, O. N., Hishikawa, Y., Yamanoi, A., Nagasue, N. (2005) Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 103, 588-598.
128. Wang, L., Wu, W. Z., Sun, H. C., Wu, X. F., Qin, L. X., Liu, Y. K., Liu, K. D., Tang, Z. Y. (2003) Mechanism of interferon α on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J. Gastrointest. Surg. 7, 587-594.
129. Asakawa, M., Kono, H., Amemiya, H., Matsuda, M., Suzuki, T., Maki, A., Fujii, H. (2006) Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int. J. Cancer 118, 564-570.
130. Wang, Y., Kato, N., Hoshida, Y., Otsuka, M., Taniguchi, H., Moriyama, M., Shiina, S., Kawabe, T., Ito, Y. M., Omata, M. (2004) UDP- glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in Japanese patients with hepatitis C virus infection. Clin. Cancer Res. 10, 2441-2446.
131. Nagao, M., Nakajima, Y., Kanehiro, H., Hisanaga, M., Aomatsu, Y., Ko, S., Tatekawa, Y., Ikeda, N., Kanokogi, H., Urizono, Y., Kobayashi, T., Shibaji, T., Kanamura, T., Ogawa, S., Nakano, H. (2000) The impact of interferon γ receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma. Hepatology 32, 491-500.
132. Legrand, A., Vadrot, N., Lardeux, B., Bringuier, A. F., Guillot, R., Feldmann, G. (2004) Study of the effects of interferon a on several human hepatoma cell lines: analysis of the signaling pathway of the cytokine and of its effects on apoptosis and cell proliferation. Liver Int. 24, 149-160.
133. Yamaji, K., Nabeshima, S., Murata, M., Chong, Y., Furusyo, N., Ikematsu, H., Hayashi, J. (2006) Interferon-α/β upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-α/β treatment. Cancer Immunol. Immunother. 55, 394-403.
134. Wheelhouse, N. M., Chan, Y. S., Gillies, S. E., Caldwell, H., Ross, J. A., Harrison, D. J., Prost, S. (2003) TNF-α induced DNA damage in primary murine hepatocytes. Int. J. Mol. Med. 12, 889-894.
135. Shimizu, Y., Iwatsuki, S., Herberman, R. B., Whiteside, T. L. (1991) Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors. Cancer Immunol. Immunother. 32, 280-288.
136. Shiraki, K., Yamanaka, T., Inoue, H., Kawakita, T., Enokimura, N., Okano, H., Sugimoto, K., Murata, K., Nakano, T. (2005) Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. Int. J. Oncol. 26, 1273-1281.
137. Romieu, R., Lacabanne, V., Kayibanda, M., Antoine, B., Bennoun, M., Chouaib, S., Guillet, J. G., Viguier, M. (1997) Critical stages of tumor growth regulation in transgenic mice harboring a hepatocellular carcinoma revealed by distinct patterns of tumor necrosis factor-α and transforming growth factor-β mRNA production. Int. Immunol. 9, 1405-1413.
138. Ryschich, E., Lizdenis, P., Ittrich, C., Benner, A., Stahl, S., Hamann, A., Schmidt, J., Knolle, P., Arnold, B., Hammerling, G. J., Ganss, R. (2006) Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res. 66, 198-211.
139. Radaeva, S., Sun, R., Pan, H. N., Hong, F., Gao, B. (2004) Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39, 1332-1342.
140. Chabicovsky, M., Wastl, U., Taper, H., Grasl-Kraupp, B., Schulte-Hermann, R., Bursch, W. (2003) Induction of apoptosis in mouse liver adenoma and carcinoma in vivo by transforming growth factor-β1. J. Cancer Res. Clin. Oncol. 129, 536-542.
141. Murata, T., Ohshima, T., Yamaji, M., Hosaka, M., Miyanari, Y., Hijikata, M., Shimotohno, K. (2005) Suppression of hepatitis C virus replicon by TGF-β. Virology 331, 407-417.
142. Wagner, K., Peters, M., Scholz, A., Benckert, C., Ruderisch, H. S., Wiedenmann, B., Rosewicz, S. (2004) Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells. Gastroenterology 126, 1828-1843.
143. Moran, D. M., Mayes, N., Koniaris, L. G., Cahill, P. A., McKillop, I. H. (2005) Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma. Liver Int. 25, 445-457.
144. Szabo, G., Catalano, D., Bellerose, G., Mandrekar, P. (2001) Interferon α and alcohol augment nuclear regulatory factor-κB activation in HepG2 cells, and interferon α increases pro-inflammatory cytokine production. Alcohol. Clin. Exp. Res. 25, 1188-1197.
145. Tsutsumi, T., Suzuki, T., Moriya, K., Yotsuyanagi, H., Shintani, Y., Fujie, H., Matsuura, Y., Kimura, S., Koike, K., Miyamura, T. (2002) Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 304, 415-424.
146. Perlemuter, G., Letteron, P., Carnot, F., Zavala, F., Pessayre, D., Nalpas, B., Brechot, C. (2003) Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model. J. Hepatol. 39, 1020-1027.
147. Sundstrom, S., Ota, S., Dimberg, L. Y., Masucci, M. G., Bergqvist, A. (2005) Hepatitis C virus core protein induces an anergic state characterized by decreased interleukin-2 production and perturbation of mitogen-activated protein kinase responses. J. Virol. 79, 2230-2239.
148. Majumder, M., Steele, R., Ghosh, A. K., Zhou, X. Y., Thornburg, L., Ray, R., Phillips, N. J., Ray, R. B. (2003) Expression of hepatitis C virus non-structural 5A protein in the liver of transgenic mice. FEBS Lett. 555, 528-532.
149. Yoshida, T., Hanada, T., Tokuhisa, T., Kosai, K., Sata, M., Kohara, M., Yoshimura, A. (2002) Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J. Exp. Med. 196, 641-653.
150. Ohno, H., Kaneko, S., Lin, Y., Kobayashi, K., Murakami, S. (1999) Human hepatitis B virus X protein augments the DNA binding of nuclear factor for IL-6 through its basic-leucine zipper domain. J. Med. Virol. 58, 11-18.
151. Yu, F. L., Liu, H. J., Lee, J. W., Liao, M. H., Shih, W. L. (2005) Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. J. Hepatol. 42, 520-527.
152. Su, F., Theodosis, C. N., Schneider, R. J. (2001) Role of NF-κB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. J. Virol. 75, 215-225.
153. Lin, S. J., Shu, P. Y., Chang, C., Ng, A. K., Hu, C. P. (2003) IL-4 suppresses the expression and the replication of hepatitis B virus in the hepatocellular carcinoma cell line Hep3B. J. Immunol. 171, 4708-4716.
154. Chen, C. J., Yang, H. I., Su, J., Jen, C. L., You, S. L., Lu, S. N., Huang, G. T., Iloeje, U. H. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65-73.
155. Kountouras, J., Boura, P., Kouklakis, G. (2002) Locoregional immunochemotherapy in hepatocellular carcinoma. Hepatogastroenterology 49, 1109-1112.
156. Wang, X. H., Qin, Y., Hu, M. H., Xie, Y. (2005) Dendritic cells pulsed with hsp70-peptide complexes derived from human hepatocellular carcinoma induce specific anti-tumor immune responses. World J. Gastroenterol. 11, 5614-5620.
157. Andrews, K. J., Ribas, A., Butterfield, L. H., Vollmer, C. M., Eilber, F. C., Dissette, V. B., Nelson, S. D., Shintaku, P., Mekhoubad, S., Nakayama, T., Taniguchi, M., Glaspy, J. A., McBride, W. H., Economou, J. S. (2000) Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. Cancer Res. 60, 6457-6464.
158. Margalit, M., Shibolet, O., Klein, A., Elinav, E., Alper, R., Thalenfeld, B., Engelhardt, D., Rabbani, E., Ilan, Y. (2005) Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes. Int. J. Cancer 115, 443-449.
159. Junbo, H., Li, Q., Zaide, W., Yunde, H. (1999) Receptor-mediated interleukin-2 gene transfer into human hepatoma cells. Int. J. Mol. Med. 3, 601-608.
160. Putzer, B. M., Stiewe, T., Rodicker, F., Schildgen, O., Ruhm, S., Dirsch, O., Fiedler, M., Damen, U., Tennant, B., Scherer, C., Graham, F. L., Roggendorf, M. (2001) Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes. J. Natl. Cancer Inst. 93, 472-479.
161. Peron, J. M., Couderc, B., Rochaix, P., Douin-Echinard, V., Asnacios, A., Souque, A., Voigt, J. J., Buscail, L., Vinel, J. P., Favre, G. (2004) Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12. J. Gastroenterol. Hepatol. 19, 388-396.
162. Wang, Z., Qiu, S. J., Ye, S. L., Tang, Z. Y., Xiao, X. (2001) Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma. Cancer Gene Ther. 8, 751-758.
163. Zager, J. S., Delman, K. A., Malhotra, S., Ebright, M. I., Bennett, J. J., Kates, T., Halterman, M., Federoff, H., Fong, Y. (2001) Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol. Med. 7, 561-568.
164. He, P., Tang, Z. Y., Liu, B. B., Ye, S. L., Liu, Y. K. (1999) The targeted expression of the human interleukin-2/interferon α2b fused gene in α-fetoprotein-expressing hepatocellular carcinoma cells. J. Cancer Res. Clin. Oncol. 125, 77-82.
165. Bui, L. A., Butterfield, L. H., Kim, J. Y., Ribas, A., Seu, P., Lau, R., Glaspy, J. A., McBride, W. H., Economou, J. S. (1997) In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum. Gene Ther. 8, 2173-2182.
166. Dumortier, J., Schonig, K., Oberwinkler, H., Low, R., Giese, T., Bujard, H., Schirmacher, P., Protzer, U. (2005) Liver-specific expression of interferon γ following adenoviral gene transfer controls hepatitis B virus replication in mice. Gene Ther. 12, 668-677.
167. Peng, B. G., Liu, S. Q., Kuang, M., He, Q., Totsuka, S., Huang, L., Huang, J., Lu, M. D., Liang, L. J., Leong, K. W., Ohno, T. (2002) Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn. J. Cancer Res. 93, 363-368.
168. Gotsman, I., Alper, R., Klein, A., Rabbani, E., Engelhardt, D., Ilan, Y. (2002) Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice. Cancer 94, 406-414.
169. Wu, M. J., Weng, C. Y., Ding, H. Y., Wu, P. J. (2005) Anti-inflammatory and antiviral effects of Glossogyne tenuifolia. Life Sci. 76, 1135-1146.
170. Mueller, M. M., Fusenig, N. E. (2004) Friends or foes - bipolar effects of the tumor stroma in cancer. Nat. Rev. Cancer 4, 839-849.
171. Pollard, J. W. (2004) Tumor-educated macrophages promote tumor progression and metastasis. Nat. Rev. Cancer 4, 71-78.
172. Budhu, A., Forgues, M., Ye, Q. H., He, P., Zanetti, K. A., Kammula, U. S., Chen, Y., Qin, L. X., Tang, Z. Y., Wang, X. W. (2006) Prediction of venous metastases, recurrence and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10, 99-111.
173. Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A. (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549-555.
174. De Visser, K. E., Korets, L. V., Coussens, L. M. (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423.